A股異動 | 誠邁科技競價跌停 否認直接參與華為鴻蒙系統建設
格隆匯10月21日丨誠邁科技(300598.SZ)競價跌停,報71.65元,成交3625萬元,總市值57億元。10月20日晚,最近9個交易日收穫8個漲停板的華為概念股誠邁科技回覆深交所關注函表示,公司對相關傳聞進行了核查,公司目前不持有武漢深之度科技有限公司任何股權。公司未直接參與華為鴻蒙系統建設,未直接參與鴻蒙核心技術的研發,鴻蒙系統相關業務暫對公司收入影響較小。2019年上半年,來自華為的收入為9229.11萬元,公司總收入為29285.54萬元,華為佔比為31.51%。公司與華為公司的合作可能存在單一客户收入集中等風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.